argenex SE (NASDAQ:ARGX) Receives $986.78 Average Price Target from Analysts

Shares of argenex SE (NASDAQ:ARGX) have been assigned an average rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $986.7778.

Several brokerages have recently weighed in on ARGX. Zacks Research cut shares of argenex from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 22nd. Piper Sandler raised their price target on argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a report on Tuesday, November 4th. Wells Fargo & Company boosted their target price on shares of argenex from $1,264.00 to $1,317.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Weiss Ratings restated a “hold (c)” rating on shares of argenex in a research note on Wednesday, January 21st. Finally, HC Wainwright lifted their price objective on shares of argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research note on Friday, October 31st.

argenex Stock Performance

argenex stock opened at $847.72 on Tuesday. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The company has a market capitalization of $52.46 billion, a PE ratio of 36.40, a P/E/G ratio of 0.56 and a beta of 0.38. The company has a 50 day moving average price of $853.69 and a 200-day moving average price of $779.43.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping the consensus estimate of $4.37 by $0.03. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%. On average, analysts forecast that argenex will post 3.13 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Ashton Thomas Private Wealth LLC acquired a new position in argenex in the 4th quarter worth approximately $248,000. UBS Group AG lifted its stake in argenex by 12.3% during the 4th quarter. UBS Group AG now owns 60,384 shares of the company’s stock valued at $50,780,000 after acquiring an additional 6,591 shares during the period. Legacy Capital Group California Inc. boosted its holdings in shares of argenex by 17.2% in the 4th quarter. Legacy Capital Group California Inc. now owns 748 shares of the company’s stock valued at $629,000 after acquiring an additional 110 shares during the last quarter. HB Wealth Management LLC increased its stake in shares of argenex by 7.1% in the fourth quarter. HB Wealth Management LLC now owns 362 shares of the company’s stock worth $305,000 after acquiring an additional 24 shares during the period. Finally, M&T Bank Corp increased its stake in shares of argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after acquiring an additional 774,916 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.